Breaking News


QoL and health-related utility analysis of adult atopic dermatitis patients treated with topical tacrolimus or corticosteroids


A post-hoc analysis of a 6-month, multicenter, double-blind, randomized phase III trial comparing tacrolimus ointment 0.1% with a topical corticosteroid regimen (1% hydrocortisone acetate or butyrate) was conducted. The dataset comprised 926 patients with moderate-severe atopic dermatitis (AD) with a mean age of 32.8 years. The aim of this analysis was to assess the mean change in quality of life (QoL) and estimate health-related utility in the two groups. QoL was assessed by the Short Form 36 questionnaire (SF36) and health-related utility by the EQ5 Index. All QoL domains of the SF36 improved significantly in favor of the tacrolimus group apart from "physical functioning" (P = 0.106). At 1 month, there ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list